Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Insulin Resistance and Breast Cancer
This study is currently recruiting participants.
Verified by National Institutes of Health Clinical Center (CC), November 2008
Sponsored by: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00304941
  Purpose

This study will characterize risk factors associated with breast cancer development in some patients. In particular, it will examine the role of insulin in breast cancer in patients with and without a family history of the disease.

Women 30 to 70 years old who have been diagnosed with breast cancer and matched control healthy subjects with and without a family history of breast cancer may be eligible for this study.

Participants undergo the following procedures:

  • Cancer-genetic counseling session, including family history, risk assessment, genetic testing for BRCA1 and BRCA2 (if criteria is met), interpretation of results and management options
  • Medical history, including questions about symptoms or diseases, reproductive history, use of oral contraceptives, body weight, exercise, lifestyle, and demographic issues
  • Drawing of family tree
  • Examination of medical records
  • Blood drawing for genetic and other tests
  • CT scan of the abdomen (approximate time < 1 minute)
  • Filling out questionnaires

Condition
Breast Cancer
Insulin Resistance

Genetics Home Reference related topics: breast cancer
MedlinePlus related topics: Breast Cancer Cancer Genetic Counseling
Drug Information available for: Insulin
U.S. FDA Resources
Study Type: Observational
Study Design: Prospective
Official Title: Insulin Resistance and Breast Cancer: Implications for Preventive Counseling in Familial and Sporadic Cases

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 336
Study Start Date: March 2006
Detailed Description:

The etiology of breast cancer is still poorly understood with known risk factors explaining only a small proportion of cases. Risk factors that modulate the development of breast cancer include: age, geographic location, socioeconomic status, reproductive events, exogenous hormones, lifestyle, familial history of breast cancer, mammographic density, history of benign breast disease, ionizing radiation, and bone density.

Several lines of evidence have demonstrated that insulin and the insulin receptor play a key role in the formation and progression of breast cancer. Insulin has direct and indirect effects on breast cancer; direct effects as a growth promoting factor and indirect effects through actions on other hormones involved in breast cancer. In addition, certain conditions associated with insulin resistance, such as obesity and abdominal fat, are known risk factors for breast cancer.

Family history of breast cancer is also a well established major risk factor. To date, both genetic and non-genetic factors have been suggested to influence breast cancer risk in women with a positive family history of breast cancer including those with recognized mutations in the BRCA1 and BRCA2 genes. Women with a family history of breast cancer inherit a susceptibility to the condition; the development of the disease requires a series of promoting steps including lifestyle, diet, and environmental factors. Several hormones involved in breast cancer such as IGF-1, testosterone, and SHBG are affected by a positive family history of breast cancer. Also, women with a high Waist-to-Hip ratio (WHR) and a positive family history of breast cancer are at higher risk of developing breast cancer than those women with a high WHR without a positive family history. The role of insulin and insulin-related factors in women with a family history of breast cancer has not been examined.

There is growing recognition that insulin may be a potential mediator of breast cancer. The above evidence suggests that actions of insulin may be involved in the promoting steps that predispose some women to breast cancer. These findings provide the biological basis for insulin related factors to serve as potential targets for breast cancer prevention and risk assessment.

The main goal of this proposal is to unravel the contributions of insulin and insulin-related actions (e.g. insulin resistance, abdominal fat) on breast cancer risk. The purpose of the present study is to characterize the role of insulin in newly diagnosed premenopausal and postmenopausal women with and without a family history of breast cancer. The objective is to assess the relative strength of each risk factor associated with insulin actions and their individual impact on breast cancer. This study will provide data that may serve as the basis for future studies on preventive strategies targeted at lowering insulin levels and increasing insulin sensitivity (e.g. decrease glucose, decrease abdominal fat, decrease omega-6 fatty acids/increase omega-3 fatty acids, increase fiber intake, increase exercise) in a subset of patients.

This protocol will recruit only female patients, and will concentrate only on breast cancer risk. Subjects will be asked to complete several questionnaires in the course of genetic counseling to provide information on medical and reproductive history, demographics, risk factors, physical activity as well as other information needed to establish an appropriate sample for the study. Genetic testing will be offered as part of the initial evaluation and to check for BRCA1/2 mutation status.

  Eligibility

Ages Eligible for Study:   30 Years to 70 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria
  • ELIGIBILITY CRITERIA:

Females (ages 30-70 years old) who have been diagnosed with breast cancer and age matched controls with and without a family history of breast cancer.

The actual selection of patients most appropriate for research and clinical training needs will be made by protocol investigators.

Referrals will be accepted from the patient recruitment office of the NIH, genetic counselors, geneticists, oncologists, and other health care providers in the area or anybody who reads the information about the study on the NIH world wide web site.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00304941

Contacts
Contact: Patient Recruitment and Public Liaison Office (800) 411-1222 prpl@mail.cc.nih.gov
Contact: TTY 1-866-411-1010

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
  More Information

NIH Clinical Center Detailed Web Page  This link exits the ClinicalTrials.gov site

Publications:
Study ID Numbers: 060119, 06-CH-0119
Study First Received: March 17, 2006
Last Updated: December 12, 2008
ClinicalTrials.gov Identifier: NCT00304941  
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Breast Cancer
Family History
Pre/Post Menopausal
Prevention
Risk-Factor
Body-Mass-Index
BRCA1
Insulin
Genetic Counseling
Penetrance
Risk Assessment
Breast Cancer
BRCA1
Family History
Risk Assessment
Healthy Volunteer
HV

Study placed in the following topic categories:
Hyperinsulinism
Metabolic Diseases
Skin Diseases
Breast Neoplasms
Healthy
Insulin Resistance
Metabolic disorder
Glucose Metabolism Disorders
Insulin
Menopause
Breast Diseases

Additional relevant MeSH terms:
Neoplasms
Hypoglycemic Agents
Neoplasms by Site
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009